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Abstract. Background: The Ca2+-binding protein calretinin
(CR), while absent in normal colonocytes, is expressed in the
majority of poorly differentiated colon carcinomas, and is
hypothesized that mutations in the distal part (from exon 7 to
10) of the CR gene (CALB2) could be responsible for the
aberrant CR expression. Materials and Methods: Using PCR
amplification of genomic DNA and restriction fragment length
polymorphism analysis, four single nucleotide polymorphisms
(SNPs) were identified in CALB2 intron 9. Results: A
significant positive association between the genotype at SNP513
and colon cancer was found: more C/T heterozygotes were
found in patients with colon tumors (60%) compared to
healthy controls (35%) or patients with lung tumors (38%).
Our results indicate that C/T heterozygosity at position 513 is
linked to CR expression in colon tumors and colon cancer cell
lines, suggesting a link with increased carcinogenesis.
Conclusion: The SNP513 in human CALB2 may thus be a
predictive marker for colon tumors.
In Western countries, colorectal cancer is the second
leading cause of cancer-related deaths and in many
instances, the disease is diagnosed too late. Incurable cancer
is detected in approximately one quarter of patients, and
one half of patients who undergo surgery will ultimately
develop metastases (1). Thus, an early detection method,
when curative therapies are still effective, would be the most
promising strategy. The 2000 guidelines of the American
Cancer Society for the early detection of colon cancer
include the fecal occult blood test, flexible sigmoidoscopy
and colonoscopy (2). Evaluation of molecular alterations in
fecal DNA was proposed as a potential, noninvasive,
alternative tool; mutations in p53 (TP53) and K-ras (KRAS)
were detected in approximately one third of cases with a
minimal or no co-presence of these gene alterations (3).
Moreover, a null-mutation of the glutathione S-transferase
T1 (GSTT1) results in a statistically significant increased
risk for gastric cancer (4), which has been confirmed in a
recent SNP interaction study (5). Hence, a better
understanding of tumor biology at the molecular level would
also help to identify novel determinants of response to
chemotherapy in colon cancer (6) and/or to identify patients
with the highest probability of responding to therapy.
Calretinin (CR) and the alternatively spliced form
calretinin-22k (CR-22k) are members of a large family of
Ca2+-binding proteins possessing respectively six and four
(7) highly conserved Ca2+-binding motifs, which are
referred to as EF-hand domains (8). CR is mainly expressed
in specific neurons in the central and peripheral nervous
system (9), and in several other organs, e.g. testis and ovary.
The exact role played by CR in the various cell types
remains unknown, but suggested functions include a general
role as Ca2+-buffer in non-excitable cells, an involvement in
the excitability of neurons expressing this protein (10), and
a function in neuroprotection against excitotoxicity (11, 12).
CR is expressed in several colon adenocarcinoma cell lines
(13) and also in primary colon tumors (14). Recently,
antibodies against CR have gained much attention as
specific and sensitive markers for mesotheliomas, tumors of
the pleura of the lung, mainly of the epithelioid and the
mixed type (15, 16). It is important to note that the smaller
isoform CR-22k (Mr 22 kDa) arising from deletion of exons
8 and 9 in the CR mRNA has been observed only in
transformed tissue and derived cell lines (17, 18). Although
the function of both isoforms in tumor cells is not yet clear,
transfection of CR-negative colon carcinoma cells (Caco-2)
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with plasmids coding for CR or CR-22k increases their
resistance towards the growth-inhibiting effect of butyrate
(19), a substance known to induce the differentiation
process in enterocytes. Conversely, treatment of CR-
expressing human colon adenocarcinoma WiDr cells with
butyrate leads to a down-regulation of CR (20).
Several factors affect splicing, the most obvious being
mutations in the 5’ or 3’ branch sites, but also variations in
the activity and/or quantity of general splicing factors may
cause alternative splicing. The third mechanism is negative
regulation by the binding of factors that inhibit splicing. We
hypothesized that mutations in the 5’ or 3’ branch sites
might be responsible for the alternative splicing. We thus
sequenced the 3’ region of exon 7, the 5’ region of intron 7
and the region containing the junction intron 9/exon 10 of
DNA that was isolated from normal tissue, colon cancer cell
lines and primary colon cancer biopsies. Besides the
canonical splice donor/acceptor sites, other intron motifs
also appear to play a role in correct splicing. Introns are
believed to play a role in gene regulation and in some cases
enhance susceptibility to cancer (21). For instance,
polymorphisms and germ line mutations in intron 6 of TP53
(tumor suppressor gene) apparently predispose individuals
with specific single nucleotide polymorphism (SNP) alleles
to cancer (22-24). In addition, a mutation in intron 3 of the
calpain gene (CAPN1) is associated with type 2 diabetes
mellitus (25). Thus in addition to sequencing intron/exon
junctions, we searched for SNPs in introns 7 and 9 of the
human calretinin (CALB2) gene. 
Materials and Methods
Samples. Genomic DNA from 19 colon tumor samples was
obtained from the University Hospital of Bern, Switzerland
(Institute of Medical Oncology, Prof. M. Fey). Paraffin sections
from an additional 57 colon tumors were obtained from R.
Weimann (Department of Pathology, Inselspital, Bern: 35
samples) and J. P. Musy, (Kantonsspital Luzern: 22 samples,
previously described (14)). All patients resided in or near the
Canton of Bern. The average age of the patients when the
samples were taken was 65±14 years. As a first control group,
blood samples were used from 152 apparently healthy individuals
who were considered to be eligible "healthy" blood donors for the
Blutspendedienst in Bern and who resided in the same area as the
patient group. To qualify as blood donors, participants had to be
free of infection with HIV, HBV and HCV, not be IV drug users
or have been diagnosed for any form of cancer. The large
majority of individuals in both groups were Caucasian. The local
ethical committee had approved the collection of these blood
samples. The samples were anonymized; hence, tracing back to
patients and blood donors was not possible. The second control
group consisted of 50 samples of lung tumor DNA also received
from the Department of Pathology, Inselspital, Bern (average
patient age: 64±8 years). These samples were obtained from
patients with the same geographic and ethnic background as those
in the other two groups.
The following cell lines were obtained from the American Type
Culture Collection (ATCC): SW480, SW620, WiDr, HT-29,
SW1116, Lovo, Colo205, Caco-2, SK-CO-1, LS180 and Met-5A.
Co112 and Co115/3 cells were a gift of Dr. B. Sordat, Swiss Institute
for Experimental Cancer Research, Epalinges, and the
mesothelioma cell lines SPC212, SPC111, ZL55, ZL5, ZL34 were a
gift from Dr. R. Stahel, University Hospital, Zurich, Switzerland.
Details relating to the cell culturing conditions of the colon cancer
and the mesothelioma cell lines are to be found in the literature (13,
26, respectively). Other cell lines included: K562 (chronic myeloid
leukemia cells); KG1 (hematopoietic progenitor cells); MOLT-4
(lymphoblastic leukemia cells); HL-60 and KG1 (myelogenous
leukemic cells), MDA-MB-453 (breast cancer cells); SKUT-1B
(uterine tumor cells); Calu-1 (lung carcinoma cells); WI38 (lung
embryonic fibroblast cells); IMR90 (embryonic fibroblasts); A549
(non-small cell lung cancer cells); SaOs-2 (osteosarcoma cells). 
Isolation of genomic DNA, PCR analyses, DNA sequencing and
restriction fragment length polymorphism (RFLP) analyses. Genomic
DNA from different cell lines (Supplemental Table S I and Table
I) and from paraffin sections was isolated using standard methods.
Genomic DNA (0.5-1 Ìg) was used for the PCR analyses. For this,
two regions in intron 9 of the CALB2 gene were amplified. The
Supplemental Table S I. CALB2 intron 9 SNPs of normal colon tissue
and four colon carcinoma cell lines.
Cell line/Clone # Pos. 242 363 491 513
SNP G/T C/T C/T C/T 
Human (DOE institute)* G T T C
normal colon/1 G C C C
normal colon/6 G C C C
normal colon/10 G C C C
WiDr /1 G C C T
WiDr /3 G C C T
WiDr /6 G C C C
Colo205/1 G C C T
Colo205/2 G C C T
Colo205/3 G C C T
Co115-3/3 G T T C
Co115-3/4 T T T C
Co115-3/5 G T T C
CaCo-2/2 G T T C
CaCo-2/6 G T T C
CaCo-2/7 G T T C
* An additional sequence in the Genebank by the DOE Joint Genome
Institute (definition: Homo sapiens chromosome 16 clone CTD-
2520I13; accession: AC106736, GI:1942485) was found to be identical
to the CALB2 genome sequence. Differences between the sequences
were seen at four positions (first nucleotide of intron 9 is position 1).
Genomic DNA was amplified by PCR, the fragments were cloned into
a sequencing vector and DNA from three E. coli colonies/samples were
sequenced.
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primer pair 244F and 427R and the pair 438F and 629R yielded
fragments of 184 and 192 base pairs, respectively. The primer
sequences were: 244F: ACTAGGGTGTGACCACGCTGT; 427R:
GTTATGAAGAAAACCACCGGAGT; 438F: GGTAAACTTTA
AATAGCCCCCG; 629R: GGGTGTTCAGATCGTGTAATGA.
The amplicons from several cell lines and from a control colon
tissue sample were cloned in a plasmid vector by TOPO-Cloning
(Invitrogen, LuBioScience GmbH, Lucerne, Switzerland) and
sequenced (Microsynth AG, Balgach, Switzerland). For the RFLP
analyses, PCR product fragment A was digested with MnlI to check
for position 363, fragment B was digested with either MnlI (pos.
491) or NlaIII (pos. 513). The digested fragments were separated
either on 2% agarose or on 6% polyacrylamide gels, and the gels
were stained with ethidium bromide. As controls for the RFLP
analyses, PCR products from the cell line-derived clones (Table S
I), where the genotype (C or T) at the given SNP was determined
by DNA sequencing, were used as controls. For instance, clones 1
and 6 from WiDr cells have either a T or a C at SNP 513,
respectively. Thus at this site, NlaIII cuts the PCR fragment B of
clone 6 (C), but not of clone 1 (T). 
Table I. A) SNPs at positions 363, 491 and 513 of CALB2 intron 9 of various cell lines.
# SNP pos. 363 491 513 CR* # SNP pos. 363 491 513 CR*
sample sample
normal colon C/C C/C C/C -
1 Caco-2 C/T C/T C/C - 15 SK-CO-1 C/C C/C C/T +
2 K562 C/C C/C C/C - 16 WI38 C/T C/C C/T +
3 KG1 C/T C/C C/C - 17 IMR90 C/T C/C C/T +
4 HL-60 C/T C/T C/C - 18 Co112 C/C C/C C/T +
5 MDA-MB-453 T/T T/T C/C - 19 SPC212 C/C C/C T/T +
6 SW1116 C/C C/C T/T - 20 Colo205 C/T C/T C/T +
7 MOLT-4 C/C C/C T/T - 21 A549 C/T C/T C/T +
8 SKUT-1B C/C C/C T/T - 22 SaOs-2 C/T C/T C/T +
9 ZL5 C/C C/C T/T - 23 SPC111 C/T C/T C/T ++
10 Lovo C/C C/C C/C +/– 24 Co115/3 C/T C/T C/T ++
11 SW480 C/C C/C C/C +/– 25 LS180 C/C C/T C/T ++
12 SW620 C/C C/C C/C +/– 26 HT-29 C/C C/T C/T ++
13 Calu-1 C/C C/C T/T +/– 27 ZL55 T/T C/C C/C ++
14 ZL34 C/C C/C T/T +/– 28 WiDr C/C C/T C/T +++
*Colon cancer cell lines are marked in bold and mesothelioma cell lines in italics. CR expression levels were determined by Western blot analyses
and were qualitatively classified as follows: (–) no expression, (+/–) weak expression, (+) moderate expression, (++) strong expression and
(+++) very strong expression. For the ANOVA analysis, the values 0, 0.5, 1, 2 and 3 were attributed to the above qualitative classifications,
respectively. Values for colon cancer (13) and mesothelioma cells (26) were taken from previous reports and compared to the expression levels in
the other cell lines (Western blots not shown). Heterozygous samples (C/T; bold) at position 513 are strongly correlated with elevated CR
expression levels in all cell lines (one-way ANOVA; F2,25=8.1, p=0.002); Analysis of seven CR-positive and five CR-negative colon cancer cells
(bold) also show significant differences with respect to C/T heterozygosity at position 513 (Fisher's exact test (p=0.015). The other two loci show
no correlation between haplotype and CR expression (SNP 363: F2,25=0.1, p=0.92; SNP 491: F2,25=0.4, p=0.66).
B) Relative distribution of C/C, C/T ad T/T at SNPs 363, 491 and 519 in cell lines with no (–) or low (+/–) CR expression (left panel) and in 
CR-positive (+ – +++) lines (right panel).
"Low" CR (cell lines 1-14) "High" CR (cell lines 15-28)
Intron position, Genotype Number % Intron position, Genotype Number %
restriction enzyme of lines restriction enzyme of lines
363, MnlI C/C 10 71.4% 363, MnlI C/C 6 42.9%
C/T 3 21.4% C/T 7 50%
T/T 1 7.2% T/T 1 7.1%
491, MnlI C/C 11 78.6% 491, Mnll C/C 8 57.2%
C/T 2 14.3% C/T 5 35.7%
T/T 1 7.1% T/T 1 7.1%
513, NlaIII C/C 8 57.1% 513, NlaIII C/C 1 7.1%
C/T 0 0% C/T 12 85.8%
T/T 6 42.9% T/T 1 7.1%
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Western blot analysis and immunohistochemistry. Soluble proteins
from different cell lines were isolated as described elsewhere (27),
separated by SDS-PAGE, transferred onto nylon membranes and
probed with the antiserum CR7696 recognizing CR and CR-22k
(28). Immunohistochemistry was performed on 39 non-small cell
lung cancer (NSCLC) and 57 colon cancer samples using the same
CR antibody and the same protocol as described elsewhere (18).
The stained sections were analyzed by light microscopy by two
observers not knowing the results from the genetic analysis. Each
section was evaluated twice within a period of 3-6 months. The
tumors were classified according to the staining intensity and the
size of the immunoreactive area within the tumor mass. Based on
the two parameters the values 0, 0.5, 1, 1.5 or 2 were attributed to
each sample. 
Statistical analysis. To compare the level of CR expression scores
among SNP genotypes, the Kruskal-Wallis test, as implemented
in the SAS statistical software (PROC NPAR1WAY; SAS
Institute Cary, NC, USA) was used. This approach is more
appropriate than ANOVA, since the expression scores are in
arbitrary units and unlikely to be normally distributed.
Additionally, we divided the cell lines into two categories: low
expression (score <1) and high expression (score ≥1), and used
Fisher's exact test to test for independence between this class
assignment and SNP genotype; this test is a replacement for a
¯2 test when the sample size is small (29). To test for differences
in genotype and allele frequencies between the groups of
subjects (colon and lung cancer patients and healthy blood
donors), we used both Pearson's ¯2 test and Fisher's exact test.
Since the two tests yielded congruent results, only those from
the ¯2 tests are reported. 
Results
The alternative splice product CR-22k has so far been
detected only in tumor samples of the colon (30), in
mesotheliomas (18) and in cell lines derived from these
tumor types (17). Based on the hypothesis that mutations
in the 5’ or 3’ branch sites cause the alternative splicing,
we sequenced the 3’ region of exon 7/ intron 7 and the 3’
end of intron 9/ exon 10 from normal colon and primary
colon cancer biopsies as well as from colon cancer cell
lines (WiDr, Colo205, Caco-2, Co115/3). Both junctions
were identical in all samples, excluding that alternative
splicing in tumor samples (tissue and cell lines) was due
to incorrect splice donor, splice acceptor and branch sites
in introns 7 and 9 (Figure 1). Moreover, the 3’ end of
intron 7 and the 5’ end of intron 9 were found to be
unaltered between DNA from normal tissue and tumor
cells. Since other motifs in intron sequences also seem to
play a role in correct splicing, the entire sequences of
CALB2 introns 7 and 9 were analyzed. The intron 7
sequence (313 base pairs, Figure 1) from the same four
cancer cell lines as above and from normal colon tissue
were all identical. In contrast, the complete sequence of
CALB2 intron 9 (740 base pairs) revealed four SNP sites
(Table S I). A C/T polymorphism at three of the sites
(pos. 363, 491 and 513) and a G/T polymorphism at
position 242 were observed. The small number of
sequences (three clones for each sample) did not allow us
to determine the genotype with certainty at the various
SNP positions. Hence, three of the SNPs were
investigated by RFLP analysis. At positions 363, 491 and
513, sites for the restriction enzymes MnlI and NlaIII
enabled us to ascertain whether a C or a T was present in
the two alleles. Genomic DNA from the various cell lines
was amplified by either PCR primer pairs 1 or 2 yielding
fragments A or B of 184 and 192 base pairs, respectively
(Figure 2). Fragment A contained SNP 363 (MnlI) and
fragment B SNPs 491 (MnlI) and 513 (NlaIII). PCR
fragments A and B were subsequently digested with the
appropriate enzymes yielding different fragments that
permitted an identification of the genotype (Figure 2).
There was no association between CR expression of
tumor cell lines and the CALB2 genotype at either SNP 363
or SNP 491 (Table I; Kruskal-Wallis test: p>0.5 in both
cases). In contrast, the expression of CR clearly differed
among the SNP 513 genotypes (Kruskal-Wallis test,
¯2=12.6, df=2, p=0.002). The C/T heterozygotes were over-
represented in lines with moderate to high expression (score
≥1, odds ratio (OR): 21.0, 95% confidence interval (CI):
2.9-151.4; Fisher's exact test: p<0.003), while all nine lines
with no CR expression were C/C or T/T homozygotes. Pair-
wise comparisons indicated that tumor cell lines
heterozygous for SNP 513 had on average significantly
higher CR expression levels than both C/C homozygotes
(Kruskal-Wallis test: ¯2=8.8, df=1, p=0.003) and T/T
homozygotes (¯2=8.7, df=1, p=0.003). There was no
difference between the two homozygous genotypes
(¯2=0.01, df=1, p=0.95). These results also held true when
only colon cancer lines (bold in Table I) were compared.
The seven C/T cancer lines had significantly higher
expression scores than the four C/C colon cancer lines
(¯2=6.0, df=1, p=0.015) and C/T lines had a significantly
lower probability of having low or no CR expression
(Fisher's exact test: p=0.015).
These data indicate that the heterozygous genotype at
SNP 513 may be linked to calretinin expression, which in
turn is associated with colon tumors (14). We thus set out
to test the relationship between the SNP genotype at
position 513 (as well as at positions 363 and 491) and
susceptibility to colon cancer using genomic DNA from 76
colon tumor samples. As a first control group, we used
blood samples from 152 apparently healthy individuals
(males and females of various ages with a similar ethnic
background to the colon tumor patients) who, based on
their general health status, were eligible for donating blood.
To exclude the possibility that C/T heterozygosity is non-
specifically associated with any tumor type, 50 lung cancer
samples were also analyzed. 
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The frequencies of the three genotypes (C/C, C/T, T/T)
at position 513 differed between the colon cancer patients
(n=76) and the healthy control group (¯2=13.7, df=2,
p<0.0011), and between the colon and lung cancer patients
(¯2=8.4, df=2, p=0.015); there was no difference between
the healthy controls and lung cancer patients (¯2=3.1, df=2,
p=0.21). These last two groups were at Hardy-Weinberg
equilibrium with respect to SNP 513 (healthy subjects:
¯2=0.1, df=1, p=0.78; lung cancer patients: ¯2=2.75, df=1,
p=0.09). In contrast, the samples of colon cancer patients
showed a significant excess of heterozygotes over the Hardy-
Weinberg expectation (¯2=10.5, df=1, p=0.0012). In a
direct comparison, the C/T genotype was more frequent
among colon cancer patients (60%) than between the
healthy controls (35%) and the lung cancer patients (38%).
The frequency of the C/C homozygotes showed an opposite
pattern (37% in colon cancer patients versus 62% and 59%
in lung cancer patients and healthy controls, respectively).
The C/T:C/C OR between colon cancer patients and
controls was 2.8 (95% CI: 1.6-5.0, ¯2=12.4, df=1,
p=0.0004); the analogous OR between colon and lung
cancer patients was 2.7 (95% CI: 1.3-5.6, ¯2=7.0, df=1,
p=0.0082). The T/T homozygotes were too rare to allow a
meaningful comparison between samples. The frequency of
allele T among the colon cancer patients was 0.33 and was
significantly higher than among the healthy controls (allele
frequency: 0.23, ¯2=4.7, p=0.030) and the lung cancer
patients (allele frequency: 0.19, ¯2=5.9, p=0.016); there was
no indication of a difference between healthy and lung
cancer samples (¯2=0.8, p=0.36).
For a subset of 57 colon tumor and 39 lung cancer cases,
we also had access to tissue paraffin sections, which we
stained for CR (Tables IIA and III). Of the 57 tissue
sections from colon cancer patients, 44 (77%) were
considered to be CR-immunoreactive (defined as an IHC
score >0.25), a value that is in line with previous findings
Figure 1. A) Genomic DNA sequence of CALB2 intron 7 from normal colon tissue and four colon carcinoma cell lines. DNA sequences from all
samples were identical. Splicing donor and acceptor sites: 5’ GT (U in the RNA) and 3’ AG are underlined. Exon sequences are given in small capital.
The splicing consensus sequence CTCTAAC (bold) confers to the expected sequence (Py80NPy80Py87Pu75APy95) which is present 18-40 bp upstream of
the 3’ splice site (Pu: G, A/Py C, T). B) Genomic DNA sequence of CALB2 intron 9 from normal colon tissue. Splicing donor and acceptor sites: 5’ GU
and 3’ AG are underlined. Exon sequences are given in small capital. The splicing consensus sequence GGTTGAC (bold) confers to the expected
sequence with the exception of the first nucleotide (underlined), which is most often Py, but in CALB2 intron 9 is G. Sequences of primers 244F and 427R
yielding a PCR fragment of 184 bp are given in italics. Primers 438F and 629R (PCR fragment size: 192 bp) are given in italics and underlined. Boxed
sequences indicate restriction sites for MnlI (CCTC) and NlaIII (CATG); the SNPs within the boxes are marked in bold.
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where approximately 60-70% of GIII colon tumors were
found to be CR-immunoreactive (14). The average IHC
score determined semi-quantitatively for the samples with
the C/T genotype was slightly higher than for the C/C
genotype (0.89±0.55, n=33 vs. 0.70±0.45, n=22;
average±SEM), but the difference was not statistically
significant. Furthermore, no pathological characteristics, in
particular grading (p=0.61; ¯2-test) or stage (p=0.18) were
associated with the SNP 513 polymorphism status. The
percentages of GI, GII and GIII tumors with C/C (14%,
50% and 36%) were practical identical to the ones in the
C/T group (15%, 52% and 33%). As shown before (14, 30),
in some samples, cells of the tumor mass were distinctly CR-
positive, while in other samples mainly giant fibroblastic
cells were stained by the CR antiserum and crypt cells in
these samples were largely CR-negative (not shown). The
fibroblastic cells were always restricted to particular regions
of the tumor, often surrounding the tubular organotypical
tumor formations.
No significant differences were detected in genotype or
allele frequencies at the other two SNP sites (363 and 491;
Table IIB) between the healthy and the colon tumor patient
groups (all p>0.19). This indicates that it is specifically SNP
513 that is differently distributed in colon tumors vs. healthy
controls or lung tumors. In contrast, the lung cancer patients
carried more often T/T and less often C/C at SNP 363 than
either the healthy group (p=0.006) or the colon cancer
patient group (p=0.010). This was reflected in the higher
frequency of allele T at SNP 363 among the lung cancer
patients (0.40) than either among healthy individuals (0.27,
p=0.016) or the colon cancer patients (0.22, p=0.008).
Therefore, C/T heterozygosity at CALB2 SNP 513 might
be a risk factor and/or a predictive marker for colon tumors.
Evidently, this statement is only valuable if the C/T
heterozygosity is not the result of a spontaneous mutation
in the tumor tissue itself. In a relatively small number of
samples (n=4), we had access to genomic DNA from the
tumor and normal tissue of the same patient. The SNPs at
all four loci tested were always identical, irrespective of the
tissue origin (tumor vs. normal). This indicates that these
SNPs are not the result of somatic mutations occurring
during tumorigenesis, but are germ line polymorphisms.
Discussion
Genetic alterations, in particular loss of tumor suppressor
genes including APC (adenomatous polyposis coli), DCC
(deleted in colon carcinoma) and TP53 (31) are observed in
>70% of colon tumors, but also the up-regulation of
oncogenes such as K-ras or myc is typical. A null mutation in
glutathione S-transferase T1 (GSTT1), an enzyme implicated
in the detoxification of carcinogens and subsequently
preventing DNA damage, is considered as a risk factor in
increasing the susceptibility to gastric cancer (4, 5).
Deregulated CR expression is seen in colon carcinomas
(14) and in the many CR-positive colon cancer cell lines (13).
While CR expression is observed in essentially all
mesotheliomas of the epithelioid and mixed type (15, 16, 32),
Figure 2. Haplotype analysis in CALB2 intron 9 at SNP 491 and at SNP
513. A) Schematic diagram of CALB2 intron 9 with primers used for PCR
amplification yielding fragments A and B. Fragment A is digested with
MnlI (reveals haplotype at position 363) and fragment B with either MnlI
or NlaIII (positions 491 and 513, respectively). SNP sites are marked with
*. B) Digestion of PCR fragment B (192 bp) with MnlI results in two
fragments of 135 and 57 bp, if a C is present at position 491. C) Digestion
of fragment B with NlaIII amplified from three healthy control samples
representing the three genotypes C/T, C/C and T/T. Digestion results in
three fragments (79, 59, 54 bp) in the case of C (middle lane) and in two
fragments (138 and 54 bp) in the case of T (right lane). Samples were run
on 6% PAA gels for improved resolution. The upper faint bands in the
middle lane (C/C) are the result of incomplete digestion. In B) and C),
DNA marker V (Roche) was used. Sizes of fragments are (in bp) from top
to bottom: 267, 234, 213, 192, 184, 124, 123, 104, 89, 80, 64, 57.
Underlined fragments are marked by bars in C.
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CR expression in colon cancer is clearly linked to the degree
of tumor differentiation. Whereas only a small percentage
(6%) of GI tumors are CR-immunoreactive, almost 67% of
GIII tumors express this protein (14), suggesting that CR
expression is increased as tumor cells dedifferentiate. This
correlates with higher CR expression levels in vitro in poorly
differentiated colon carcinoma cells with a high proliferation
rate (13). Alternative splicing of the CR mRNA restricted to
tumor cells in vitro and in vivo (18, 30) gives rise to the splice
forms CR-20k and CR-22k (33). This finding prompted us to
search for putative mutations in the CALB2 gene in the
region from exon 7 to exon 10, where the alternative splicing
event occurs. No differences in the splice donor or acceptor
sites were evident between colon cancer cells and normal
colon tissue. However, four SNPs were detected in the
CALB2 intron 9 sequence. Three of these SNPs (position
363, 491 and 513) were accessible for RFLP analysis. In cell
lines, a clear association existed between CR expression and
C/T heterozygosity at SNP 513. Higher CR expression levels
were detected in cell lines with the 513 C/T genotype and this
was validated by comparing all 28 cell lines as well as the 12
colon cancer lines. Interestingly, all cell lines with confirmed
CR-22k expression (WiDr, HT-29, LS-180, COLO205 and
Co115/3 (17)) display the 513 C/T genotype (Table IA).
Hence, the question was raised as to whether the 513
C/T genotype is also over-represented in primary colon
cancer specimens retrieved during surgery. Clearly the
frequency of C/T heterozygotes was significantly higher in
the colon cancer patient group compared to the healthy
control group and lung tumor group. A good association
existed between CR-immunoreactive colon tumors with
SNP 513 C/T (27/46; 59%) and CR-immunoreactive colon
cell lines (7/12; 58%), even though the latter were rather
small in number. Heterozygosity is the most likely reason
for the excess of C/T heterozygotes in the colon cancer
group, but the overall number of T/T homozygotes was
too small to entirely exclude the possibility that the
increased CR expression is due to a dominant effect of
the T allele. An argument against the latter point is the
fact that 6 out of the 7 cell lines with T/T at position 513
had no (4) or weak (2) CR expression. The SNPs at
position 363 and 491 did not differ between the colon
cancer group and the healthy control group. Interestingly,
T/T homozygotes with SNP 363, and the T allele
generally, were significantly more frequent in lung tumor
patients and might thus serve as an additional predictive
marker. A more detailed analysis of this haplotype at SNP
363 needs to be conducted.
Table II. A) SNP 513 analysis of genomic DNA from healthy controls (Ctrl; n=152) or from colon tumor (n=76) and lung tumor (n=50) samples. 
Ctrl Colon tumor Lung tumor
CR+ CR–* CR–** CR n.d. Total CR+ CR– CR n.d. Total
C/C 90 16 3 3 6 28 12 13 6 31
(59%) (37%) (62%)
C/T 53 27 2 4 13 46 3 11 5 19
(35%) (60%) (38%)
T/T 9 1 1 0 0 2 0 0 0 0
(6%) (3%) (0%)
Total 152 44 6 7 19 76 15 24 11 50
(100%) (100%) (100%)
Tumor samples were additionally grouped according to their CR expression status: CR-positive samples (CR+); CR-negative samples (CR–);
samples in which the CR status was not determined (n.d.). In the latter category, genomic DNA, but no tumor tissue was available for IHC. *
IHC score 0.25; ** IHC score 0
B) SNP 363 and 491 analyses.
SNP MnlI (363) MnlI (491)
Genotype
Ctrl Colon Lung Ctrl Colon Lung
C/C 83 (55%) 26 (59%) 21 (42%) 112 (74%) 34 (63%) 30 (60%)
C/T 57 (37%) 17 (39%) 18 (36%) 35 (23%) 19 (35%) 16 (32%)
T/T 12 (8%) 1 (2%) 11 (22%) 5 (3%) 1 (2%) 4 (8%)
Total 152 44 50 152 54 50
Amongst the colon samples (n=54), 10 were excluded for genotype analysis at position 363, since the genotype could not be determined
conclusively. 
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Mutations in chromosome 16 at the locus of CALB2 (Locus:
16q22.2) have been described recently. The gene closest to the
CALB2 gene locus that is linked to colon cancer is that for E-
cadherin (CDH1; Locus 16q22.1). E-cadherin participates in the
regulation of cellular adhesion and motility, interacts with ‚-
catenin and might act as a tumor suppressor through the Wnt
signaling pathway. Since loss of one CDH1 or of the related
gene cadherin-11 (CDH11) allele was detected only in a
minority of cases, the authors concluded that the two genes are
only indirectly involved in the pathogenesis of colorectal cancer
(34). However in another study, LOH at 16q22.1 was detected
in 75% (out of 50) of gastric tumors (35) and reduced
expression levels of E-cadherin and ‚-catenin were identified at
frequencies of 42% and 28%, respectively. The authors
hypothetized that alterations in E-cadherin and ‚-catenin play a
role in the initiation and progression of gastric cancer.
Subsequently, the effects of changes in the expression levels of
E-cadherin and CR work in an antagonistic way: down-
regulation of the former and de novo expression of CR in
human colon cancer cells favor the progression of these tumors
Table III. CALB2 genotype at SNP 513 of 76 colon tumors (primary or metastatic), pathological grade (grade of tumor tissue differentiation) and
analysis of 57 samples for CR expression by semi-quantitative immunohistochemistry (IHC).
Case Grade of diff. Genotype IHC * Case Grade of diff. Genotype IHC*
1 2 C/T 0.75 39 1 C/T 0.5
2 2 C/C 0.5 40 1 C/T 2
3 3 C/T 0.75 41 3 C/C 0.25
4 2 C/T 1 42 3 C/C 0.75
5 2 C/T 0.75 43 2 C/T 1
6 2 C/C 0.75 44 1 C/T 0.75
7 3 C/T 0.25 45 1 T/T 1.75
8 3 C/T 0.75 46 1 C/C 0.75
9 3 C/T 0 47 1 C/C 0.75
10 2 T/T 0.25 48 1 C/C 0.5
11 2 C/C 1 49 2 C/T 1
12 2 C/T 1 50 3 C/T 0
13 2 C/C 0 51 2 C/C 1
14 3 C/C 0.75 52 2 C/C 0.25
15 3 C/C 0.75 53 3 C/T 0
16 3 C/T 1 54 2 C/T 1.75
17 3 C/C 1 55 2 C/T 2
18 2 C/C 0.75 56 1 C/T 0.75
19 3 C/T 0.5 57 1 C/T 0
20 2 C/T 1 58 n.d. C/T n.d.
21 2 C/C 0 59 n.d. C/T n.d.
22 2 C/T 0.75 60 n.d. C/T n.d.
23 3 C/C 1 61 n.d. C/C n.d.
24 2 C/T 0.25 62 n.d. C/T n.d.
25 2 C/C 0 63 n.d. C/T n.d.
26 3 C/C 0.25 64 n.d. C/C n.d.
27 2 C/T 0.75 65 n.d. C/C n.d.
28 2 C/T 1 66 n.d. C/C n.d.
29 2 C/T 0.75 67 n.d. C/T n.d.
30 2 C/C 0.75 68 n.d. C/T n.d.
31 3 C/T 1 69 n.d. C/T n.d.
32 3 C/C 1 70 n.d. C/T n.d.
33 3 C/T 1 71 n.d. C/T n.d.
34 3 C/T 1 72 n.d. C/T n.d.
35 2 C/C 0.5 73 n.d. C/T n.d.
36 2 C/T 0.5 74 n.d. C/C n.d.
37 2 C/T 1.5 75 n.d. C/C n.d.
38 2 C/T 0.75 76 n.d. C/T n.d.
For each tumor, the tumor grade (pathological classification) and the semi-quantitative immunohistochemical analysis (IHC) in two independent
evaluations were performed at an interval of 3 months. The tumors were classified according to the staining intensity and the size of the
immunoreactive area within the tumor mass. Based on the two parameters the values 0, 0.5, 1, 1.5 or 2 were attributed to each sample. The average
for the two analyses is shown. 33/57 (58%) of the colon tumors analyzed by IHC and 46 of a total of 76 samples (60%) were heterozygous (C/T;
bold) at SNP 513. From samples 58-76, only genomic DNA was available and neither the grade nor the IHC score could be determined (n.d.).
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and are probably independently regulated. However butyrate,
a known inducer of differentiation in enterocytes has been
shown to enhance the expression of E-cadherin (36) and at the
same time to down-regulate CR expression in vitro (19, 37). The
decrease in CR expression is linked to the differentiation status
of colon carcinoma cells, since in HT-29 cells subjected to
glucose starvation, the CR expression levels and differentiation
were markedly lower than in untreated cells (38).
How might particular SNPs be associated with
increased susceptibility for certain tumor types?
Obviously, missense mutations in the coding region of a
gene may lead to subtle alterations in structure and
modify/inhibit the interaction with targets (DNA,
proteins). Several examples of this type have been shown
for TP53 missense mutations (39). More and more,
mutations in non-coding regions including 5’ untranslated
regions (UTR), 3’ UTR (40) and intronic sequences (41,
42) seem to be highly linked to certain tumor types.
Interestingly, an over-representation of heterozygotes was
often associated with the tumor phenotype. Yet only in
rare cases was the SNP genotype correlated with the
expression levels of the particular gene product. Since
intronic sequences in tumor suppressor genes (e.g. TP53)
are implicated in gene expression and DNA-protein
interactions (23), the fact that heterozygosity is linked to
the tumor phenotype in the above examples hints that
subtle gene-dosage effects may be involved.
Our results indicate that specifically heterozygosity at SNP
513 of the CALB2 gene, and not one of the homozygote
genotypes (C/C or T/T), appears to be associated with
elevated CR levels in colon tumors. In previous studies, SNP
heterozygosity was reportedly associated with an increased
risk for specific cancers. An increased heterozygote frequency
was observed in: (i) the 3’ UTR of the CDK2A gene coding
for the two gene products p16INK4a and p14ARF in sporadic
primary melanomas (40), (ii) intron 2 of the calcium channel
subunit CACNA2D2 in small cell lung cancer (41), (iii) intron
2 of CDKN1A (p21WAF1/Cip1), a downstream effector of p53
in breast cancer (42), and (iv) exon 18 (a silent C/T
transition) of the candidate oncosupressor gene RAD54L in
human meningiomas (43). In contrast to our study, neither
the mRNA nor protein levels of the affected genes were
measured in the previous investigations. Thus, it is generally
unknown whether heterozygosity at a particular SNP is linked
to altered protein expression, as in our case, where CR
protein levels were found to be elevated in colon tumors with
the heterozygous (C/T) genotype. CR expression per se is
probably not directly pro-oncogenic in colon cells. Hence, CR
cannot be viewed as a classical proto-oncogene. However,
CR-containing colon cells are more resistant to signals that
induce their differentiation (19). CR expression could thus
facilitate their acquirement of additional mutations, which
would lead to a more malignant, dedifferentiated phenotype. 
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